
Panagiotis Konstantinopoulos MD PhD
Gynecologic Cancer, Hematologic Oncology
Velma Eisenson Endowed Chair for Clinical and Translational Research, Director Mellen and Eisenson Family Center for BRCA and Related Genes Dana-Farber Cancer Institute, Professor of Medicine Harvard Medical School
Join to View Full Profile
450 Brookline AveBoston, MA 02215
Dr. Konstantinopoulos is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Panagiotis (Panos) Konstantinopoulos, MD, PhD is Director of the Mellen and Eisenson Family Center for BRCA and Related Genes and Director of Translational Research, Division of Gynecologic Oncology. He is also the Velma Eisenson Endowed Chair for Clinical and Translational Research at DFCI and Professor of Medicine at Harvard Medical School. His clinical and translational research career focuses on ovarian and endometrial cancers with a focus on the areas of DNA Damage and Repair and Immunotherapy. His research efforts in this area have been supported by the Department of Defense (DOD), Ovarian Cancer Research Program (OCRP), the American Association of Cancer Research (AACR) and the NIH/NCI. As a clinical researcher, he is involved as a principal investigator (PI) and co-investigator in multiple gynecologic cancer clinical trials and serves as Co-Chair of the NRG Development Therapeutics (Translational Science) Committee. After receiving his MD and PhD from University of Patras in Greece, Dr Konstantinopoulos completed internship and residency at State University of New York at Syracuse, followed by a medical oncology fellowship at Beth Israel Deaconess Medical Center and Harvard Medical School. He also received a Master's degree in Clinical Investigation from Harvard Medical School and Massachusetts Institute of Technology (MIT) Department of Health Sciences and Technology.
Education & Training
- Harvard - MIT Health Sciences and TechnologyMMSc, Clinical Investigation, 2008 - 2010
- Beth Israel Deaconess Medical CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
- SUNY Upstate Medical UniversityResidency, Internal Medicine, 2002 - 2005
- University of Patras School of MedicineClass of 1997
Certifications & Licensure
- FL State Medical License 2022 - Present
- MA State Medical License 2005 - 2025
- NH State Medical License 2023 - 2025
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- Avastin in Patients With Epithelial Ovarian, Primary Peritoneal Serous or Fallopian Tube Cancer Start of enrollment: 2009 Mar 01
- Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Start of enrollment: 2011 Mar 01
- A Phase II, 2-Stage, 2-Arm PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer Start of enrollment: 2011 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcoma.Kevin Tyan, Kevin X Liu, Alicia C Smart, Colleen M Feltmate, Neil S Horowitz
Gynecologic Oncology. 2025-03-08 - 3 citationsFeasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomi...Rachel A Pozzar, Andrea C Enzinger, Catherine Howard, Anna Tavormina, Ursula A Matulonis
Gynecologic Oncology. 2024-09-01 - 3 citations53BP1 loss elicits cGAS-STING-dependent antitumor immunity in ovarian and pancreatic cancer.Yajie Sun, Jeffrey Patterson-Fortin, Sen Han, Zhe Li, Zuzanna Nowicka
Nature Communications. 2024-08-06
Lectures
- Phase 2, two-group, two-stage study of avelumab in patients (pts) with microsatellite stable (MSS), microsatellite instable (MSI), and polymerase epsilon (POLE) mutate...2019 ASCO Annual Meeting - 6/1/2019
- TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian ca...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Other
- DYNLL1 Binds to MRE11 to Limit DNA End Resection in BRCA1-Deficient CellsPanagiotis Konstantinopoulos, MD, Nature
https://www.doximity.com/articles/804b7938-38f7-46ed-bc4f-f3b8235a8ea6
UpToDate, Wolters Kluwer Health - 2012-12-13
Press Mentions
- New Class of Cancer Drug Halts Tumor Growth in Early Human TrialsJune 23rd, 2020
- New Research Shows Which Ovarian Cancer Patients Won't Benefit from Immune-PARP ComboMarch 19th, 2020
- Avelumab Active in Mismatch Repair-Deficient Endometrial CancerOctober 3rd, 2019
- Join now to see all
Grant Support
- Targeting Replication Stress and DNA Damage Response in Uterine CancerDANA-FARBER CANCER INST2024–2029
- Targeting CDK7 in CCNE1-amplified Ovarian CancerSTANFORD UNIVERSITY2022–2027
- Targeting CDK7 in CCNE1-amplified Ovarian CancerSTANFORD UNIVERSITY2022–2027
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: